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Infant acute lymphoblastic leukemia (ALL) with rearrangement
of the mixed-lineage leukemia (MLL) gene shows a poor
outcome, despite intensive chemotherapy followed by hemato-
poietic stem cell transplantation at ﬁrst remission.
1 Furthermore,
therapy-related late effects, including short stature and neuro-
endocrinological complications, remain problematic.
2 This
current situation has prompted us to establish a novel treatment
for infant ALL based on a new concept. In the present study, we
veriﬁed the feasibility of adoptive immunotherapy for MLL
gene-rearranged infant ALL using T lymphocytes genetically
engineered by WT1-speciﬁc T-cell receptor (TCR) gene transfer.
Construction of a novel retrovirus vector expressing
HLA-A*24:02-restricted WT1-speciﬁc TCR with silencing of
the endogenous TCR gene has been reported previously.
3 The
TCR-a and TCR-b chain genes were cloned from an
HLA-A*24:02-restricted WT1235 243-speciﬁc CD8
þ cytotoxic
T lymphocyte (CTL) clone, TAK-1.
4 Retrovirus transduction into
CD8
þ T lymphocytes was performed as described previously.
3
Brieﬂy, CD8
þ T lymphocytes were isolated from peripheral
blood mononuclear cells of healthy individuals using CD8
þ
cell-isolating immunomagnetic beads (MACS beads; Miltenyi
Biotec, Auburn, CA, USA). CD8
þ T lymphocytes were then
cultured in RPMI1640 medium containing 10% human serum,
anti-CD3 monoclonal antibody (OKT3), interleukins (IL)-2, IL-7,
IL-15 and IL-21 for 3 days. The CD8
þ T lymphocytes were then
transduced with retrovirus vector using the RetroNectin-bound
virus infection method in which retroviral solutions were
preloaded onto RetroNectin (Takara Bio, Shiga, Japan)-coated
plates, and centrifuged at 2000 g for 2h. Retrovirus vector-
transduced CD8
þ T lymphocytes were then cultured in the
medium described above for a further 10–14 days. Using this
method, more than 60% of CD8
þ T lymphocytes appeared to
be positive for WT1235 243 peptide/HLA-A*24:02 tetramer
staining. We used these cells as WT1-speciﬁc TCR gene-
transduced effector cells, that is, WT1-TCR CTLs, for further
experiments.
We ﬁrst examined WT1 expression in infant ALL cell samples
obtained from bone marrow of the patients using quantitative
real-time polymerase chain reaction of WT1 mRNA and
glyceraldehyde-3-phosphate dehydrogenase mRNA as an inter-
nal control, as reported previously.
5 Approval for this study was
obtained from the institutional review boards of Ehime
University Hospital and hospitals registered by the Japan
Pediatric Leukemia-Lymphoma Study Group. Written informed
consent was obtained from all patients and healthy volunteers in
accordance with the Declaration of Helsinki. As shown in
Figure 1a, expression of WT1 mRNA appeared to be signiﬁ-
cantly higher in leukemia cells of ALL infants with MLL gene
rearrangement (n¼41) than in those of ALL patients with germ-
line conﬁguration (n¼19) (t-test; Po0.01). The expression of
WT1 mRNA was extremely low or undetectable in normal
peripheral blood mononuclear cells. We also examined the
expression of WT1 protein in leukemia cell lines and normal
peripheral blood mononuclear cells. As shown in Figure 1b,
WT1 protein appeared to be expressed abundantly in all ALL
cell lines with MLL rearrangement and K562 cells, but not in
normal peripheral blood mononuclear cells.
Next, we examined the cytotoxicity of WT1-TCR CTLs against
various leukemia cell lines using standard
51Cr-release assays.
The results are shown in Figure 2a. WT1-TCR CTLs exerted
cytotoxicity against the HLA-A*24:02-positive ALL cell lines
with MLL rearrangement (KOCL69, KOPB26, and KOCL44) but
not against the HLA-A*24:02-negative ALL cell lines with MLL
rearrangement (KOCL45 and KOCL51). The K562 cell line,
which is negative for HLA expression and sensitive to natural
killer cell-mediated cytotoxicity, also appeared to be resistant to
the cytotoxicity mediated by WT1-TCR CTLs. As shown in
Figure 2b, the cytotoxicity mediated by WT1-TCR CTLs against
ALL cell lines with MLL rearrangement was signiﬁcantly inhibited
by addition of anti-HLA class I framework monoclonal antibody
but not by anti-HLA-DR monoclonal antibody. These results
show that WT1-TCR CTLs can exert cytotoxicity against ALL cell
lines with MLL rearrangement in an HLA-A*24:02-restricted
manner through recognition of the WT1235 243 epitope that is
naturally processed from WT1 protein in ALL cells and presented
on the cell surface in the context of HLA class I molecules.
Finally, we examined whether WT1-TCR CTLs can lyse infant
ALL cells with MLL rearrangement freshly isolated from the
patients. As expected, all HLA-A*24:02-positive leukemia cells
were lysed by WT1-TCR CTLs; however, HLA-A*24:02-negative
leukemia cells were resistant to WT1-TCR CTL-mediated
cytotoxicity (Figure 2c). As we have reported previously,
4
WT1-speciﬁc CTLs did not exert cytotoxicity against normal
cells (data not shown). Taken together, the data suggested that
WT1-TCR CTLs appeared to be capable of discriminating infant
ALL leukemia cells from normal cells in an HLA-restricted manner.
In the present study, we demonstrated that adoptive immuno-
therapy for chemotherapy-resistant infant ALL with MLL
rearrangement using T lymphocytes, genetically engineered by
WT1-speciﬁc TCR gene transfer is feasible, based on the
following ﬁndings. First, WT1 appeared to be abundantly
expressed in most cases of infant ALL, especially those with
MLL rearrangement, which is the most frequent chemotherapy-
resistant infant leukemia. Second, T lymphocytes, genetically
engineered by WT1-speciﬁc TCR gene transfer, efﬁciently
lysed leukemia cells isolated from infants with ALL as well as
cell lines with MLL rearrangement, but not normal cells, in an
HLA-restricted manner.
WT1 is known to have an essential role in development of the
kidney and genitourinary system in fetuses. On the other hand,
WT1 expression after birth is limited to very few tissues, and its
expression level in normal tissues is extremely low. In contrast
to the low expression level of WT1 in normal cells, WT1 is
expressed abundantly in various kinds of acute leukemia.
6 In
addition, WT1 is reportedly expressed in chemotherapy-resistant
leukemia stem cells.
7 Using in vitro and in vivo experimental
systems, we and other groups have previously revealed that
WT1-speciﬁc CTLs never induce cell and tissue damage.
4,8
These ﬁndings indicate that cell-mediated immunotherapy for
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Figure 1 WT1 expression in leukemia and normal cells. (a) WT1 mRNA expression in infant ALL cells with or without MLL rearrangement and
normal peripheral blood mononuclear cells. Expression levels of WT1 mRNA in bone marrow cells of patients with infant leukemia and peripheral
blood mononuclear cells of healthy individuals were examined by quantitative real-time polymerase chain reaction. The level of WT1 mRNA
expression in infant ALL cases with MLL rearrangement was signiﬁcantly higher than in those with germ-line MLL gene (Po0.01). (b) Expression of
WT1 protein in leukemia cell lines and normal peripheral blood mononuclear cells by western blotting. WT1 protein was abundantly expressed in
infant ALL cell lines with MLL rearrangement, and also in K562 cells.
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Figure 2 Cytotoxicity of WT1-TCR CTLs against infant ALL cells with MLL rearrangement. (a) Cytotoxicity of WT1-TCR CTLs against infant ALL
cell lines. The cytotoxicity of WT1-TCR CTLs against HLA-A*24:02-positive and HLA-A*24:02-negative infant ALL cell lines with MLL
rearrangement, and also the K562 cell line, was determined by 5-h
51Cr-release assays at effector/target ratios of 20:1, 10:1 and 5:1. (b) HLA class I
restriction of cytotoxicity mediated by WT1-TCR CTLs against infant ALL cells. The cytotoxicity of WT1-TCR CTLs against infant ALL cell lines with MLL
rearrangement was determined by 5-h
51Cr-release assays at an effector/target ratio of 5:1 in the presence or absence of anti-HLA class I framework
monoclonal antibody or anti-HLA-DR framework monoclonal antibody. (c) Cytotoxicity of WT1-TCR CTLs against freshly isolated infant ALL cells with
MLL rearrangement freshly isolated from the patients, as determined by 5-h
51Cr-release assays at effector/target ratios of 40:1, 20:1 and 10:1.
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Blood Cancer Journalmalignancies targeting WT1 is effective and safe. In view of the
fact that infant ALL is chemotherapy-resistant and that
the indications for hematopoietic stem cell transplantation are
limited, in addition to the high prevalence of severe therapy-
related adverse events after hematopoietic stem cell transplanta-
tion, the clinical efﬁcacy of gene-immunotherapy using
WT1-speciﬁc TCR gene transfer would be considerably
advantageous.
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